Table 3.

BrdU Labeling Index in CK19-TAg Transgenic Mouse Lesions

Urothelium		CIS	Invasive TCC
Non-transgenic	Transgenic		Substromal	Muscle
0.5 ± 0.3%	0.5 ± 0.5%	10.3 ± 4.7%	33 ± 6%	29 ± 6%

CIS, carcinoma in situ; TCC, transitional cell carcinoma. See text for description of lesions. Calculated as percentage of examined nuclei that were immunohistochemically positive for BrdU staining. For nontransgenic urothelium at each age, n = 2 mice. For all others, n ≥ 5 mice. For each lesion type except CIS, multiple microscopic fields were counted in each mouse, totaling at least 1000 nuclei examined. For CIS, all visible nuclei were examined.